Moderna (MRNA) jumped 177% on Wednesday, and the strangest part is how little news it took. A $200 million estimate change moved $30 billion on the stock market.
Moderna became famous for its COVID vaccine five years ago, and its stock price is now at its highest since mid-2024. So, investors wasted no time taking profits after such a massive rally.
But can the stock price climb further? Or will the rally stop here?
What Actually Made Moderna Jump 130%?
The drug did not do it alone. Leerink’s revised estimate raised its 2032 sales estimate by roughly $200 million. Yet, the stock moved 150 times that amount in a market already at record highs.
Five loaded conditions did the rest. Moderna had collapsed 95% from $484 to $22. The recovery was already running, up 357% in 2026 on a flu approval before the cancer news.
The price sat above all six moving averages while analysts refused to believe with a $52.95 average target under the current price.
And short sellers, traders who borrow shares and sell them betting on a fall, held 13.37% short interest in the freely traded shares, losing $4.8 billion when the readout forced them to buy back.
Moderna Stock Price Prediction: What Wall Street Giants Think
The Moderna move is one of those rare biotech events where the fundamental story genuinely changed overnight. The stock still overshot the immediate fundamentals, and today’s pullback is already showing that.
Ignore the old consensus target of roughly $50. Most of those targets were published before the Phase 3 result and are effectively obsolete.
Source: BeInCrypto
